1-4 of 4
Dana Paskalis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Lindsey Roeker, Gustavo A. Fonseca, Andrea Sitlinger, Issam S. Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T. Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jakub Svoboda, Danielle M. Brander
Journal: Blood
Blood (2021) 137 (20): 2817–2826.
https://doi.org/10.1182/blood.2020007376
Published: 2021
Includes: Supplemental data
Journal Articles

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

Anthony R. Mato, MDMSCE, Jakub Svoboda, MD, Eline T. Luning Prak, MD,PhD, Stephen J. Schuster, MD, Patricia Tsao, MD PhD, Colleen Dorsey, BSN, RN, Pamela S. Becker, MD, Danielle M. Brander, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Cara M King, MPH, Beth Morrigan, Kaitlin Kennard, RN, BSN, Lindsey E. Roeker, MD, Andrew D. Zelenetz, MD PhD, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 297.
https://doi.org/10.1182/blood-2018-99-117526
Published: 2018
Journal Articles

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy

Anthony R. Mato, MD, Bruce D. Cheson, MD, Nicole Lamanna, MD, John M. Pagel, MD PhD, Frederick Lansigan, MD, Paul M. Barr, MD, Jeffrey J. Pu, MD PhD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jakub Svoboda, MD, Stephen J. Schuster, MD, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Andrea Sitlinger, MD, Chaitra S. Ujjani, MD, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Danielle M. Brander, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4314.
https://doi.org/10.1182/blood.V130.Suppl_1.4314.4314
Published: 2017
Journal Articles

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

Anthony R. Mato, MD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jessica Geoghegan, Stephen J. Schuster, MD, Jakub Svoboda, MD, Pamela S. Becker, MD PhD, Elise A. Chong, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Kaitlin Kennard, RN, BSN, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3010.
https://doi.org/10.1182/blood.V130.Suppl_1.3010.3010
Published: 2017